APOE and amyloidosis: HAE-4, an antibody (Table 4) which preferentially binds non-lipidated, aggregated forms of ApoE, was shown to reduce existing amyloid pathology in the brain parenchyma and cerebral vessels of 5xFAD mice, and to improve cerebrovascular functions as well as suppress Aβ-mediated tau propagation [205–207].